Isoliquiritigenin

961-29-5

C15H12O4

DMSO : >= 100 mg/mL (390.24 mM); Ethanol : 100 mg/mL (390.24 mM; Need ultrasonic)

Metabolic Enzyme/Protease; Autophagy

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits aldose reductase with an IC₅₀ of 320 nM. IC50 & Target: IC50: 320 nM (Aldose reductase) In Vitro: Isoliquiritigenin may prevent diabetic complications through inhibiting rat lens aldose reductase with an IC₅₀ of 320 nM and sorbitol accumulation in human red blood cells with an IC₅₀ of 2.0 uM^[1]. Isoliquiritigenin (100 uM) markedly inhibits the hypoxia-induced prolonged TPS and TR90 of cardiomyocytes. Isoliquiritigenin significantly triggers AMPK Thr172 phosphorylation as compared with vehicle group. Isoliquiritigenin treatment also induces extracellular signal-regulated kinase (ERK) signaling pathway in the cardiomyocytes. Isoliquiritigenin treatment significantly decreases the intracellular ROS levels of isolated cardiomyocytes during hypoxia/reoxygenation^[3]. Isoliquiritigenin not only downregulates IL-6 expression but also significantly decreases levels of phosphorylated ERK and STAT3 and can inhibit phosphorylation levels of ERK and STAT3 induced by recombinant human IL-6, which are critical signaling proteins in IL-6 signaling regulation networks^[4]. In Vivo: Isoliquiritigenin shows concentration-dependent inhibition of the tonic contraction of mouse jejunum induced by various types of stimulants such as CCh (1 mM), KCl (60 mM) and BaCl₂ (0.3 mM) with IC₅₀ values of 4.96+/-1.97 mM, 4.03+/-1.34 mM and 3.70+/-0.58 mM, respectively^[2]. Isoliquiritigenin exhibits significant anti-tumor activity in MM xenograft models and synergistically enhances the anti-myeloma activity of adriamycin^[4].